SCHEMBL5954446

SCHEMBL5954446

O=C1CN(S(=O)(=O)c2ccccc2)C(=S)N1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
MAPT P10636 2/20 0.63
POLB P06746 1/20 0.63
MMP2 P08253 1/20 0.56
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PKM P14618 2/20 0.49
CYP2C9 P11712 3/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2D6 P10635 1/20 0.47
HSD17B10 Q99714 1/20 0.44
PARL Q9H300 1/20 0.43
CMA1 P23946 3/20 0.41
CTSG P08311 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8972689 0.84 ALDH1A1 (0.69) ALDH1A1MAPTPOLBMMP2MEN1
SCHEMBL6797308 0.84 MMP2 (0.58) ALDH1A1MAPTPOLBMMP2MEN1
SCHEMBL9491573 0.78 ALDH1A1 (1.00) ALDH1A1MAPTPOLBMMP2MEN1
SCHEMBL10676845 0.76 MEN1 (0.51) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL10681934 0.74 RXFP1 (0.48) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL8798641 0.74 CA2 (0.47) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL10677902 0.73 HSD17B10 (0.40) ALDH1A1MAPTPOLBMMP2MEN1
SCHEMBL8799405 0.73 POLB (0.37) ALDH1A1MAPTPOLBMMP2MEN1
SCHEMBL8788603 0.73 ALDH1A1 (0.38) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL8799012 0.73 CA2 (0.46) ALDH1A1MAPTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed
US-20040116617-A1 Polymer-supported arylbis(perfluoroalkylsulfonyl)-methane JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2004-06-17 US disclosed
US-20040116417-A1 Thiohydantoins and use thereof for treating diabetes LABORATOIRES FOURNIER SA (FR) 2004-06-17 US disclosed
CN-1500081-A Thiohydantonins and use thereof for treating diabetes ʵ���Ҹ���Ү��˾ 2004-05-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 ALDH1A1 452/4885MAPT 4311/4885POLB 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.